Case Presentation: Human Corneal Endothelial Cell Transplantation Combined With Cataract Extraction And Pciol In Subject With Corneal Edema
Published 2024 - 42nd Congress of the ESCRS
Reference: PP16.03 | Type: Free paper | DOI: 10.82333/rqgm-pc57
Authors: Eris Jordan 1 , Michael Goldstein* 1 , Nysha Blender 1 , Elizabeth Yeu 2
1Clinical Affairs,Aurion Biotech,Cambridge,United States, 2Virginia Eye Consultants,Norfolk,United States;Eastern Virginia Medical School,Norfolk,United States
Purpose
To report the anatomical and functional outcomes of a subject with corneal edema and progressive nuclear sclerotic cataract who received a single intracameral cell injection of cultured human corneal endothelial cells in combination with ROCK inhibitor while concurrently undergoing cataract extraction with posterior chamber intraocular lens.
Setting
This retrospective case report presents the clinical course of a single subject with a dense progressive nuclear sclerotic cataract and corneal edema who underwent cataract extraction (CE) with posterior chamber intraocular lens (PCIOL) implantation while participating in an open-label clinical trial conducted in El Salvador.
Methods
Cataract extraction (CE) with posterior chamber intraocular lens (PCIOL) implantation was performed on one eye of one subject prior to receiving a single intracameral cell injection of cultured human corneal endothelial cells (hCECs) in combination with a Rho-associated kinase (ROCK) inhibitor. The subject underwent follow-up examinations at 1, 3, 6, and 9 months after surgery. Central corneal thickness (CCT) and best-corrected visual acuity (BCVA) were recorded out to 9 months.
Results
At baseline, CCT was 713 microns and BCVA was 1.60 LogMAR. At the 1-, 3-, 6-, and 9-month timepoints following the combined procedure (CE with PCIOL and intracameral injection of hCECs with ROCK inhibitor), central corneal thickness (CCT) decreased by 200, 222, 203, and 199 microns respectively, and mean best corrected visual acuity (BCVA) was 0.54, 0.40, 0.10 and 0.10 LogMAR respectively. There were no systemic or ocular serious adverse events (SAEs) and no graft rejection was observed.
Conclusions
This case report demonstrates that a combined intraocular procedure of a single intracameral cell injection of cultured human corneal endothelial cells with ROCK inhibitor following cataract extraction with posterior chamber intraocular lens implantation was well tolerated with a favorable safety profile.